ReNeuron to present at Advanced Therapies 2023
ReNeuron Group plc
("ReNeuron" or "the Company")
ReNeuron to present at Advanced Therapies 2023 conference
ReNeuron Group plc (AIM: RENE), a UK-based leader in stem cell derived exosome technologies , announces that the Company will be attending the Advanced Therapies 2023 conference from 14-15 March at the ExCel in London.
Randolph Corteling, Chief Scientific Officer, will be speaking at the event on Tuesday 14 March. His presentation entitled - 'CustomEXTM a new stem cell-derived drug delivery platform', will be highlighting the advantages of ReNeuron's customisable stem-cell derived exosome drug delivery platform (CustomEXTM) over current technologies. In particular, it will focus on the use of its conditional immortalisation technology to produce a range of consistent exosomes, with a natural targeting ability, at a scale relevant to clinical development.
Further information on the event can be found at: Conference (terrapinn.com) and the presentation will be made available after the event on the Company's website: https://www.reneuron.com/investors/presentations/
Dr Randolph Corteling, Chief Scientific Officer, commented: "Our CustomEX TM platform has been developed as a drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities. We are in the process of generating in vivo data with the aim to clearly differentiate ourselves from our competitors with the goal to achieve commercial validation of the platform."
CustomExTM is a register trademark of ReNeuron Limited.
ENDS
Enquiries:
|
ReNeuron |
||
|
Iain Ross, Chairman |
Via Walbrook PR |
|
|
John Hawkins, Chief Financial Officer |
|
|
|
|
|
|
|
Walbrook PR (Media & Investor Relations) |
+44 (0)20 7933 8780 or reneuron@walbrookpr.com |
|
|
Paul McManus / Alice Woodings |
+44 (0)7980 541 893 / +44 (0)7407 804 654 |
|
About ReNeuron
ReNeuron has developed a proprietary stem cell-derived, exosome-based, drug delivery platform with customisable cellular targeting capabilities for the delivery of complex drug modalities.
Through the generation of several unique and scalable exosome producer cell lines, our CustomEX™ platform can be optimised for specific tissues targets and payloads leading to improvements in therapeutic outcome and a reduction in off-target effects. ReNeuron offers a delivery mechanism for a variety of payloads such as siRNA, mRNA, proteins, small molecules and genes. Through its conditionally immortalised induced pluripotent stem cell (iPSC) platform, the Company can make allogeneic tissue cells of choice and has the potential to produce exosomes with tissue specific targeting ability.
ReNeuron's shares are traded on the London AIM market under the symbol RENE.L. For further information visit www.reneuron.com
Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
Latest directors dealings
- 20 hours ago Next
- 21 hours ago CT Private Equity Trust
- 21 hours ago Kingfisher
- 21 hours ago Kingfisher
- 21 hours ago Rio Tinto